The Drug Revolving Fund (DRF) is a self-sustaining financial mechanism designed to ensure a steady, uninterrupted supply of essential medicines in public healthcare facilities. Initiated to combat frequent stockouts caused by bureaucratic delays in government budgeting, the core philosophy relies on a continuous cycle: cash is used to buy drugs, drugs are sold to patients at affordable rates, and the proceeds are used to repurchase fresh stock. Without this revolving cycle, hospitals often experience critical drug shortages, forcing vulnerable patients to patronize unregulated patent medicine vendors.
Every functional DRF requires an initial injection of financial resources known as seed capital. This starting fund is typically provided by federal, state, or local government grants, sometimes supported by international intervention agencies. The seed capital is used exclusively to procure the first batch of essential medicines and basic pharmacy equipment. Once this initial inventory is sold to patients, the cash returns to the pool, eliminating the need for subsequent government subventions to buy stock.
The most reliable and direct source of revenue for sustaining the DRF is out-of-pocket payments made by patients receiving care at the facility. When patients pay for their prescriptions at the hospital pharmacy, the cash collected goes directly back into the drug account. These user fees must be carefully calculated to cover the actual replacement cost of the drugs, plus a small markup for operational losses and inflation, while remaining cheaper than commercial pharmacies.
With the expansion of social health insurance, formal third-party payments have become a vital funding stream for the DRF. Programs like the National Health Insurance Scheme (NHIS) and state-level health insurance agencies reimburse healthcare facilities for medications dispensed to enrolled patients. Unlike cash payments made directly by individuals, insurance claims require proper documentation, accurate coding, and timely submission of invoices to prevent cash flow delays.
External assistance from donor agencies, non-governmental organizations, and international bodies often supplements domestic DRF sources. These contributions typically arrive as targeted commodity grants—such as free shipments of antimalarials, antiretrovirals, or vaccines. While these donations reduce immediate purchasing pressures, pharmacy managers must ensure that donated items do not disrupt the revolving fund calculations or lead to unaccounted inventory discrepancies.
A well-managed DRF generates modest surpluses through careful inventory management and the inclusion of a percentage markup on drug sales. These retained earnings are not diverted to general hospital overheads; instead, they are plowed directly back into the DRF account. Reinvesting these surpluses allows the facility to expand its drug list, absorb the impact of currency devaluation, and build a financial buffer against economic shocks.
Long-term sustainability of the DRF depends on strict financial discipline, transparent auditing, and robust inventory control. Common threats to the revolving cycle include pilferage, credit sales to staff or influential persons, and failure to adjust selling prices during periods of severe inflation. Nurses and pharmacy personnel must enforce cash-and-carry policies strictly to ensure that every unit of medication dispensed translates into a collectible revenue stream for future restocking.